SCHEMBL17153234

SCHEMBL17153234

CNCCCN(C)c1ccc(-c2ccnc(Nc3cncc(CO)c3)n2)cn1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 1/20 0.40
CDK19 Q9BWU1 1/20 0.40
NR4A1 P22736 2/20 0.40
SYK P43405 3/20 0.38
IKBKB O14920 3/20 0.37
ABL1 P00519 6/20 0.37
BCR P11274 3/20 0.37
PRKCA P17252 4/20 0.36
EGFR P00533 4/20 0.36
PRKCD Q05655 3/20 0.36
SRC P12931 3/20 0.36
PDGFRB P09619 1/20 0.36
PDGFRA P16234 1/20 0.36
PRKD3 O94806 1/20 0.36
PRKCG P05129 1/20 0.36
PRKCB P05771 1/20 0.36
LCK P06239 1/20 0.36
PRKCH P24723 1/20 0.36
PRKCI P41743 1/20 0.36
ZAP70 P43403 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17153249 0.89 CDC7 (0.48) CDC7CDK19NR4A1SYKABL1
SCHEMBL17153235 0.86 CDC7 (0.44) CDC7CDK19NR4A1SYKIKBKB
SCHEMBL17153046 0.84 CDC7 (0.36) CDC7CDK19NR4A1SYKIKBKB
SCHEMBL17153105 0.84 ABL1 (0.41) CDK19SYKABL1BCREGFR
SCHEMBL12921668 0.81 ZAP70 (0.43) CDC7CDK19NR4A1SYKIKBKB
SCHEMBL6968545 0.79 ZAP70 (0.60) IKBKBPRKCAEGFRPRKCDPRKD3
SCHEMBL17153041 0.78 CDK19 (0.41) CDC7CDK19NR4A1IKBKBABL1
SCHEMBL17152807 0.77 ABL1 (0.46) IKBKBABL1BCRPRKCAEGFR
SCHEMBL17153055 0.77 CDC7 (0.46) CDC7CDK19NR4A1IKBKBABL1
SCHEMBL12921628 0.76 EGFR (0.45) CDC7CDK19IKBKBABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10017509-B2 Macrocylic pyrimidine derivatives JANSSEN PHARMACEUTICA NV (BE) 2018-07-10 US disclosed
EP-3126364-B1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2018-02-07 EP disclosed
WO-2015150555-A1 MACROCYLIC PYRIMIDINE DERIVATIVES JANSSEN PHARMACEUTICA NV (BE) 2015-10-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10017509-B2 Macrocylic pyrimidine derivatives EEF2K, VPS26B, VPS28 CDC7 1539/4885CDK19 979/4885NR4A1 3919/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.